A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea

被引：16

作者：

Kim, Jae Hui ^{[1
]}

Sagong, Min ^{[2
]}

Woo, Se Joon ^{[3
]}

Kim, Yu Cheol ^{[4
]}

Cho, Heeyoon ^{[5
]}

Lee, Young Hoon ^{[6
]}

Byon, Iksoo ^{[7
]}

Jo, Young Joon ^{[8
]}

Chin, Hee Seung ^{[9
]}

Lee, Youkyung ^{[10
]}

Chae, Jae Eun ^{[11
]}

Kang, Se Woong ^{[12
]}

机构：

[1] Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea

[2] Yeungnam Univ, Dept Ophthalmol, Coll Med, Daegu, South Korea

[3] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Seongnam, South Korea

[4] Keimyung Univ, Dept Ophthalmol, Sch Med, Daegu, South Korea

[5] Hanyang Univ, Guri Hosp, Dept Ophthalmol, Coll Med, Guri, South Korea

[6] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea

[7] Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Ophthalmol, Sch Med, Busan, South Korea

[8] Chungnam Natl Univ Hosp, Dept Ophthalmol, Daejeon, South Korea

[9] Inha Univ, Dept Ophthalmol, Sch Med, Incheon, South Korea

[10] Novartis Korea, Clin Dev & Med Affairs, Seoul, South Korea

[11] LSK Global Pharma Serv, Seoul, South Korea

[12] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea

来源：

SCIENTIFIC REPORTS | 2022年 / 12卷 / 01期

关键词：

OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; INTRAVITREAL RANIBIZUMAB; AFLIBERCEPT; GUIDELINES; AMD;

D O I：

10.1038/s41598-022-18158-z

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

To evaluate the real-world treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) in Korea, focusing on retinal fluid resolution. This multi-institutional retrospective chart review study, analyzed medical records of patients with nAMD (age >= 50 years) who received their first anti-vascular endothelial growth factor (VEGF) treatment in ophthalmology clinics across South Korea between January 2017 and March 2019. The primary endpoint was the proportion of patients with retinal fluid after 12 months of anti-VEGF treatment. The association between fluid-free period and VA gains was also evaluated. A total of 600 patients were enrolled. At baseline, 97.16% of patients had retinal fluid; after 12 months of anti-VEGF treatment, 58.10% of patients had persistent retinal fluid. VA improvements were relatively better in patients with absence of retinal fluid compared with presence of retinal fluid (+ 12.29 letters vs. + 6.45 letters at month 12; P < .0001). Longer duration of absence of retinal fluid over first 12 months correlated with better VA gains at month 12 (P < .01). More than half of the study patients with nAMD had retinal fluid even after 12 months of treatment with their current anti-VEGF. Presence of retinal fluid was associated with relatively worse VA outcomes.

引用

页数：13

共 49 条

[1]

[Anonymous], 2000, ASIA PACIFIC PERSPEC

[2] The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study [J].